Here are the finalists for the SwedenBIO Award for 2023

Genovis, Pelago Bioscience and Xbrane Biopharma are the finalists for the annual SwedenBIO Award.

SwedenBIO Award

The SwedenBIO Award is the industry’s own award and aims to provide increased visibility for life science actors by recognizing and rewarding successful and exemplary member companies that have distinguished themselves and contributed to positive attention for Swedish life science. The award has been handed out since 2007 to put the spotlight on successful and inspiring companies.

Following nominations from the industry, the jury has selected the following three finalists for the 2023 award:

Genovis provides enzymes and technologies for analytical characterization and conjugation of biopharmaceuticals. The company has launched several products and partnered with a number of international companies leading to rapid growth.

Pelago Bioscience
Spun out from the Karolinska Institute in 2013, Pelago Bioscience was founded to provide and develop the patented Cellular Thermal Shift Assay (CETSA) for use in determination and quantification of drug-target interactions.

Xbrane Biopharma
Xbrane Biopharma aims to take protein production in E. coli to the next level. The company enables their customers to produce their proteins in a controllable system, with higher yields and better quality.

The winner will be announced at our member-exclusive event, Summit, on the 30th January 2024 at Grand Hôtel in Stockholm.

The jury consist of SwedenBIO’s board: Lotta Ljungqvist, 4L Bioconsulting; Christine Wesström, Sobi; Anders Persson, AstraZeneca; Kertin Falck, Pfizer; Mårten Winge, Strike Pharma; Niels Abel Bonde, Novo Nordisk Sweden; Carl Kilander, HealthCap; Sana Alajmovic, Sigrid Therapeutics; and Torkel Gren, Recipharm.

Journalists from established news outlets are invited to attend the award ceremony, which concludes SwedenBIO Summit. Contact Afram Yakoub, Communications Manager, for more information.